The expiration of a patent for an ethical drug has only a minor effect on its market dominance. Brand loyalty towards the trademark of the off-patent drug is a barrier to the development of competition. Remedies to induce price competition are discussed, and their potential impact on drug innovation is assessed.
Get full access to this article
View all access options for this article.
References
1.
ArrowK. J. (1962), “Economic Welfare and the Allocation of Resources for Invention,” in The Rate and Direction of Inventive Activity, NelsonR., ed., Princeton, NJ: Princeton University Press.
2.
BailyM. N. (1972), “Research and Development Costs and Returns: The U.S. Pharmaceutical Industry,”Journal of Political Economy, 80(January), 70–85.
3.
BondR. S., and LeanD. F. (1977), Sales, Promotion, and Product Differentiation in Two Prescription Drug Markets, Washington, DC: U.S. Government Printing Office.
4.
Business Week (1981), “The Drive to Extend the Life of Patents,” (February 16), 29.
5.
ComanorW. (1969), “Comment” in The Economics of Drug Innovation, CooperJ. D., ed., Washington, DC: American University.
6.
ComanorW., and WilsonT. A. (1974), Advertising and Market Power, Cambridge, MA: Harvard University Press.
7.
Dougherty, Jr., A. F., Director of the Bureau of Competition, Federal Trade Commission (1979), letter to the editor, The New York Times, July 1.
8.
DunlopD. (1973), “The British System of Drug Regulation,” in Regulating New Drugs, LandauR. L., ed., Chicago: University of Chicago Press.
9.
EismanM. M. (1979), “Effective Patent Life of U.S. New Chemical Entities,” working paper, Center for the Study of Drug Development, University of Rochester.
10.
Federal Trade Commission (1979), Drug Product Selection, Washington, DC: U.S. Government Printing Office.
11.
GoldbergT. (1977), “Impact of Drug Substitution Legislation: A Report on the First Year's Experience,”Journal of the American Pharmaceutical Association, 17(April), 216–226.
12.
GoldbergT. (1979), “Evaluation of Economic Effect of Drug Product Selection Legislation,”Medical Care, 18(April), 411–419.
13.
GrabowskiH. G. (1976), Drug Regulation and Innovation: Empirical Evidence and Policy Options, Washington, DC: American Enterprise Institute for Public Policy Research.
14.
GrabowskiH. G., VernonJ. M., and ThomasL. G. (1978), “Estimating the Effects of Regulation on Innovation: An International Comparative Analysis of the Pharmaceutical Industry,”Journal of Law and Economics, 21(April), 133–163.
15.
KitchE. W. (1973), “The Patent System and the New Drug Application,” in Regulating New Drugs, LandayR. L., ed., Chicago: University of Chicago Press.
16.
MirabitoA. J. (1975), “Compulsory Patent Licensing for the United States: A Current Proposal,”Journal of the Patent Office Society, 57(July), 404–420.
17.
PeltzmanS. (1974), Regulation of Pharmaceutical Innovation: The 1962 Amendments, Washington, DC: American Enterprise Institute for Public Policy Research.
18.
PorterM. E. (1976), Interbrand Choice, Strategy, and Bilateral Market Power, Cambridge, MA: Harvard University Press.
19.
SchererF. M. (1977), The Economic Effects of Compulsory Patent Licensing, New York: New York University, Graduate School of Business Administration.
20.
SchifrinL. G. (1967), “The Ethical Drug Industry: The Case for Compulsory Patent Licensing,”Antitrust Bulletin, 12(Fall), 893–915.
21.
SchwartzmanD. (1976), Innovation in the Pharmaceutical Industry, Baltimore, MD: Johns Hopkins University Press.
22.
ShawR. W., and ShawS. A. (1977), “Patent Expiry and Competition in Polyester Fibers,”Scottish Journal of Political Economy, 24(June), 117–132.
23.
SteeleH. (1962), “Monopoly and Competition in the Ethical Drugs Market,”Journal of Law and Economics, 5(October), 131–163.
24.
Task Force on Prescription Drugs (1969), Background Papers, Washington, DC: U.S. Government Printing Office.
25.
TaylorC. T., and SilbertsonZ. A. (1973), The Economic Impact of the Patent System, Cambridge, England: Cambridge University Press.
26.
U.S. Department of Health, Education, and Welfare (1978), Approved Drug Products, Washington, DC: U.S. Government Printing Office.
27.
WardellW., and LasagnaL. (1975), Regulation and Drug Development, Washington, DC: American Enterprise Institute for Public Policy Research.
